Gonzalo Ladreda, an entrepreneur at Pockit Diagnostics, has been named in Forbes Magazine’s prestigious “Top 30 Under 30” list for Science and Healthcare. This recognition is a testament to Gonzalo’s remarkable work in the field of stroke diagnostics and his commitment to advancing healthcare through groundbreaking research.
Picture: Forbes
Based in Cambridge, Pockit Diagnostics is at the forefront of medical innovation, working tirelessly to develop a blood biomarker that can provide an early indication of the type of stroke a patient may be experiencing. With Gonzalo’s expertise, the team has made significant progress in identifying biomarkers that could revolutionize stroke diagnosis and treatment.
The work from Pockit Diagnostics has received support from the Helen Hick Stroke Foundation, committed to reducing the impact of stroke on individuals and society. The foundation recognises the potential of Pockit Diagnostics research to make a significant difference in the field of stroke diagnosis and is pleased to be supporting this study.
The research could have a profound impact on stroke patients worldwide, providing physicians with the information they need to make informed decisions about treatment options. By developing a non-invasive and cost-effective diagnostic tool, Pockit Diagnostics is working to improve patient outcomes and reduce the burden of stroke on the healthcare system.
“I am deeply honored to be included in Forbes’ Top 30 Under 30 list,” said Gonzalo Ladreda. “This recognition is a testament to the incredible work being done at Pockit Diagnostics and our shared commitment to advancing healthcare through innovation and collaboration.”
Gonzalo’s passion for science and healthcare has been a driving force in his work at Pockit Diagnostics, and his dedication to improving patient outcomes is an inspiration to all those around him. We congratulate Gonzalo on this well-deserved recognition and look forward to seeing the impact of his research in the years to come.
Comentários